Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06434337 · ClinicalTrials.gov registry record
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
A clinical trial of Human Papillomavirus, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT06434337 is a study of Human Papillomavirus that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 600 participants, below the 26,032-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06434337, a study of Human Papillomavirus, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2028-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06434337
The ClinicalTrials.gov registry entry for NCT06434337 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,032-participant average among 12 other Human Papillomavirus trials with a reported enrollment target (98% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus appearing as the primary indexed condition, and to 1 intervention - of which Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test") is the first listed.
NCT06434337 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06434337 about?
NCT06434337 is a clinical study titled "Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)". To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
What is the current status of trial NCT06434337?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-07-23. Estimated completion is 2028-03-31.
What conditions does trial NCT06434337 study?
This clinical trial studies the following conditions: Human Papillomavirus.
What interventions are being tested in trial NCT06434337?
The interventions under investigation include: Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test") (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06434337?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06434337 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provider Recommendation and HPV Vaccination
RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
RECRUITING
-
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
COMPLETED
-
Video to Promote HPV Vaccination
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.